AUR vs. RXRX
AUR (Aurora Innovation, Inc.) and RXRX (Recursion Pharmaceuticals, Inc.) are both stocks. AUR operates in Information Technology Services (Technology), while RXRX operates in Biotechnology (Healthcare). Over the past 5 years, AUR returned -4.68%/yr vs -33.81%/yr for RXRX. At a 0.43 correlation, their price movements are largely independent.
Performance
AUR vs. RXRX - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, AUR achieves a 101.04% return, which is significantly higher than RXRX's -11.74% return.
AUR
- 1D
- 3.35%
- 1M
- 25.94%
- YTD
- 101.04%
- 6M
- 93.48%
- 1Y
- 31.74%
- 3Y*
- 75.02%
- 5Y*
- -4.68%
- 10Y*
- —
RXRX
- 1D
- -4.75%
- 1M
- 6.49%
- YTD
- -11.74%
- 6M
- -16.44%
- 1Y
- -17.39%
- 3Y*
- -24.02%
- 5Y*
- -33.81%
- 10Y*
- —
AUR vs. RXRX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
AUR Aurora Innovation, Inc. | 101.04% | -39.05% | 44.16% | 261.16% | -89.25% | 12.60% |
RXRX Recursion Pharmaceuticals, Inc. | -11.74% | -39.50% | -31.44% | 27.89% | -54.99% | -25.65% |
Correlation
The correlation between AUR and RXRX is 0.52, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.52 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.44 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.44 |
Correlation (All Time) Calculated using the full available price history since May 11, 2021 | 0.43 |
The correlation between AUR and RXRX has been stable across timeframes, ranging from 0.43 to 0.52 - a consistent structural relationship.
Fundamentals
AUR:
$15.04B
RXRX:
$1.91B
AUR:
-$0.44
RXRX:
-$1.17
AUR:
3.65K
RXRX:
26.15
AUR:
7.66
RXRX:
1.86
AUR:
$4.00M
RXRX:
$66.29M
AUR:
$163.00M
RXRX:
-$22.83M
AUR:
-$882.00M
RXRX:
-$505.90M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
AUR vs. RXRX — Risk / Return Rank
AUR
RXRX
AUR vs. RXRX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Aurora Innovation, Inc. (AUR) and Recursion Pharmaceuticals, Inc. (RXRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| AUR | RXRX | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 0.52 | -0.24 | +0.76 |
Sortino ratioReturn per unit of downside risk | 1.21 | 0.16 | +1.06 |
Omega ratioGain probability vs. loss probability | 1.13 | 1.02 | +0.12 |
Calmar ratioReturn relative to maximum drawdown | 0.64 | -0.23 | +0.88 |
Martin ratioReturn relative to average drawdown | 1.10 | -0.39 | +1.49 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| AUR | RXRX | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.52 | -0.24 | +0.76 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.05 | -0.36 | +0.31 |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.06 | -0.37 | +0.31 |
Drawdowns
AUR vs. RXRX - Drawdown Comparison
The maximum AUR drawdown since its inception was -93.34%, roughly equal to the maximum RXRX drawdown of -93.13%. Use the drawdown chart below to compare losses from any high point for AUR and RXRX.
Loading charts...
Drawdown Indicators
| AUR | RXRX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -93.34% | -93.13% | -0.21% |
Max Drawdown (1Y)Largest decline over 1 year | -42.53% | -58.17% | +15.64% |
Max Drawdown (3Y)Largest decline over 3 years | -63.00% | -82.09% | +19.09% |
Max Drawdown (5Y)Largest decline over 5 years | -93.34% | -93.13% | -0.21% |
Current DrawdownCurrent decline from peak | -54.88% | -91.27% | +36.39% |
Average DrawdownAverage peak-to-trough decline | -67.47% | -75.33% | +7.86% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 24.91% | 35.04% | -10.13% |
Volatility
AUR vs. RXRX - Volatility Comparison
Aurora Innovation, Inc. (AUR) has a higher volatility of 23.30% compared to Recursion Pharmaceuticals, Inc. (RXRX) at 18.74%. This indicates that AUR's price experiences larger fluctuations and is considered to be riskier than RXRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| AUR | RXRX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 23.30% | 18.74% | +4.56% |
Volatility (6M)Calculated over the trailing 6-month period | 48.80% | 44.79% | +4.01% |
Volatility (1Y)Calculated over the trailing 1-year period | 61.01% | 73.46% | -12.45% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 90.48% | 93.46% | -2.98% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 89.91% | 93.62% | -3.71% |
Dividends
AUR vs. RXRX - Dividend Comparison
Neither AUR nor RXRX has paid dividends to shareholders.
Financials
AUR vs. RXRX - Financials Comparison
This section allows you to compare key financial metrics between Aurora Innovation, Inc. and Recursion Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
AUR and RXRX have a correlation of 0.52, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
AUR has higher volatility (23.30%) compared to RXRX (18.74%). In terms of maximum drawdown, AUR dropped -93.34% vs RXRX's -93.13%.
AUR currently has the higher Sharpe Ratio (0.52 vs -0.24), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for AUR and RXRX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer